On November 11, 2020, CR Medicon and Predicine jointly announced that it has entered into a global strategic partnership to assist biomarker-driven clinical trials and novel oncology therapeutics registration in US and China. This strategic partnership will ultimately expedite the clinical development of biopharmaceutical companies' new oncology drugs in US and China, including global clinical trial support, regulatory support, biomarker-driven drug development, and CDx development.Find out more »
About CR Medicon CR Medicon provides a full range of clinical development services, including drug and equipment registration, medical affairs, clinical operations, biological sample analysis, drug alert, data management and statistical analysis, of which the eCTD system is an integral part of our one-stop clinical CRO services. Since our founding in 2017, CR Medicon has become the clinical CRO partners for nearly a hundred well-known domestic and foreign biotech and pharmaceutical enterprises. CR Medicon team brings together the industry’s experts, has extensive experience in phase I-III new drug clinical, medical device and BE trials. and has been involved in clinical trial monitoring and project management in cutting-edge areas.